- In November 2024, Johnson & Johnson MedTech announced that it has received FDA approval for its Varipulse Pulsed Field Ablation Platform to treat atrial fibrillation. This innovative platform uses pulsed field ablation technology, offering a minimally invasive approach to address the irregular heart rhythms associated with atrial fibrillation. The Varipulse platform delivers controlled energy to targeted areas of the heart tissue, effectively restoring normal rhythm while minimizing damage to surrounding structures. The approval of this platform is expected to improve patient outcomes by providing a more precise, efficient, and safer treatment option for those suffering from atrial fibrillation
- In October 2023, Pfizer announced that the U.S. FDA has approved Velsipity for the treatment of adults with moderately to severely active ulcerative colitis. Velsipity is a novel oral medication designed to target and reduce inflammation in the digestive tract, improving symptoms and quality of life for patients suffering from this chronic condition. This approval provides a new treatment option for patients who have not responded adequately to other therapies. The approval of Velsipity offers the potential for improved disease management and better outcomes for those living with ulcerative colitis
- In October 2024, Abbott advanced its pulsed field ablation clinical studies and launched new technology to support advanced cardiac mapping. The new technology enhances the ability to map electrical signals in the heart more precisely, supporting improved treatment planning for patients with atrial fibrillation. Abbott's pulsed field ablation system, which uses targeted energy to treat irregular heart rhythms, helps reduce damage to surrounding tissues, offering a safer and more effective treatment option. This advancement is expected to improve clinical outcomes by providing more accurate and personalized care for patients undergoing cardiac procedures
